Leerink Partnrs Has Negative Outlook of TMO Q1 Earnings

Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) - Leerink Partnrs decreased their Q1 2026 earnings per share (EPS) estimates for shares of Thermo Fisher Scientific in a research note issued to investors on Monday, June 23rd. Leerink Partnrs analyst P. Souda now forecasts that the medical research company will earn $5.89 per share for the quarter, down from their prior forecast of $6.06. The consensus estimate for Thermo Fisher Scientific's current full-year earnings is $23.28 per share. Leerink Partnrs also issued estimates for Thermo Fisher Scientific's Q2 2026 earnings at $6.05 EPS, Q4 2026 earnings at $7.12 EPS and FY2026 earnings at $25.22 EPS.

TMO has been the subject of several other reports. Citigroup lowered their price target on Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating for the company in a report on Tuesday, March 4th. Royal Bank Of Canada dropped their price target on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating on the stock in a research report on Thursday, April 24th. Stifel Nicolaus cut their target price on Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating on the stock in a research note on Thursday, April 24th. Wall Street Zen upgraded Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research report on Wednesday, May 21st. Finally, Evercore ISI dropped their price target on shares of Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating on the stock in a research report on Thursday, April 24th. Four analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $604.05.

Thermo Fisher Scientific Trading Up 0.3%

Shares of Thermo Fisher Scientific stock traded up $1.37 during trading hours on Wednesday, reaching $412.02. 2,926,073 shares of the company's stock were exchanged, compared to its average volume of 1,958,976. The company has a current ratio of 1.77, a quick ratio of 1.38 and a debt-to-equity ratio of 0.64. The firm has a market capitalization of $155.53 billion, a price-to-earnings ratio of 24.17, a price-to-earnings-growth ratio of 2.13 and a beta of 0.78. The company has a fifty day moving average of $410.39 and a 200-day moving average of $485.33. Thermo Fisher Scientific has a 52-week low of $385.46 and a 52-week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, topping analysts' consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The company had revenue of $10.36 billion for the quarter, compared to the consensus estimate of $10.23 billion. During the same period in the previous year, the business earned $5.11 earnings per share. Thermo Fisher Scientific's quarterly revenue was up .2% compared to the same quarter last year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Friday, June 13th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, June 13th. This represents a $1.72 dividend on an annualized basis and a yield of 0.42%. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 10.09%.

Insider Transactions at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 300 shares of the company's stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the transaction, the executive vice president now owns 23,167 shares in the company, valued at approximately $9,960,188.31. This represents a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.33% of the company's stock.

Institutional Trading of Thermo Fisher Scientific

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Cypress Advisory Group LLC purchased a new position in Thermo Fisher Scientific in the 4th quarter worth $253,000. Intact Investment Management Inc. boosted its position in shares of Thermo Fisher Scientific by 34.0% in the 4th quarter. Intact Investment Management Inc. now owns 2,600 shares of the medical research company's stock worth $1,353,000 after purchasing an additional 660 shares in the last quarter. Purkiss Capital Advisors LLC purchased a new stake in Thermo Fisher Scientific during the 4th quarter valued at about $1,121,000. LaFleur & Godfrey LLC lifted its stake in Thermo Fisher Scientific by 9.1% during the 4th quarter. LaFleur & Godfrey LLC now owns 29,767 shares of the medical research company's stock valued at $15,486,000 after acquiring an additional 2,488 shares during the period. Finally, Deutsche Bank AG lifted its holdings in Thermo Fisher Scientific by 9.5% in the fourth quarter. Deutsche Bank AG now owns 1,321,633 shares of the medical research company's stock valued at $687,553,000 after acquiring an additional 114,277 shares during the period. Institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.